Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: Fibroblasts and Mononuclear Fibrogenic Cells Drive Right Ventricular Pulmonary Arterial Uncoupling in Pulmonary Arterial Hypertension

 


Fibroblasts and Mononuclear Fibrogenic Cells Drive Right Ventricular Pulmonary Arterial Uncoupling in Pulmonary Arterial Hypertension


AXIS

Trial Focus

Trial Focus

Heart & Circulation, Lungs & Respiratory

Objective

        

Project Description


This study involves a multidisciplinary approach with Principal Investigators that have expertise in clinical pulmonary hypertension, in molecular cardiology, and in cell and molecular biology of fibroblasts and circulating mononuclear cells.

Collectively, work by this interdisciplinary group will provide insight into abnormalities of RV-pulmonary arterial interactions in the setting of severe pulmonary hypertension and will lay the groundwork for potential new therapies.

Trial Status

Accepting Participants

Contact

Cheri Abbott RN, CCRP at 303-724-7466 or cheryl.abbott@ucdenver.edu

Location

University of Colorado HospitalUniversity of Colorado Hospital

Eligibility and Other Participant Information


Inclusion Criteria
•Only subjects that have Idiopathic PH, scleroderma with PH, scleroderma with no PH or have a Patent foramen Ovale with be considered for this study
•Subjects must be having a right heart cath as part of their clinical workup
•Subject must be at least 18 years of age
•Must be able to give informed consent
 
Exclusion Criteria
•Subjects cannot be immunodeficient
•Subjects cannot be taking an immunosuppressive agent
•Subjects cannot have coincident cardiac or pulmonary disease resulting in pulmonary hypertension (WHO categories 2-5)
•BMI cannot be >35